Table 4 Analysis of factors predicting neurological death-free survival after SRS (Fine-Gray proportional hazards model)
Covariate | P value | Hazard ratio (95% CI) |
|---|---|---|
Female Sex | 0.20 | 0.443 (0.129–1.53) |
High KPS (≥70) | 0.43 | 0.656 (0.231–1.86) |
Controlled systemic disease/no extracranial metastasis | 0.62 | 1.35 (0.417–4.35) |
Long interval from primary diagnosis to SRS (>12 months) | 0.48 | 1.41 (0.549–3.60) |
Chemotherapy | 0.25 | 0.423 (0.097–1.84) |
Solitary metastasis | 0.21 | 0.534 (0.206–1.42) |
Small cumulative PIV (≤5 mL) | 0.15 | 0.438 (0.144–1.33) |
Two-session SRS | 0.26 | 0.426 (0.095–1.91) |